Abstract: Despite remarkable advances in diagnosis and long-term management, asthma remains a serious public health concern. Newly updated expert guidelines emphasize the intraand inter-individual variability of asthma and highlight the importance of periodic assessment of asthma control. These guidelines update recommendations for step-wise asthma treatment, address the burgeoning fi eld of asthma diagnostics, and stress the importance of a patient and health care professional partnership, including written action plans and self monitoring. The fi eld of asthma therapeutics is expanding rapidly, with promising new treatment options available or in development that may address some of the existing barriers to successful asthma management. These approaches simplify treatment, use combinations of agents in one delivery device that have complementary actions, or target specifi c pathways involved in asthma pathophysiology. Considerable activity is taking place in asthma pharmacogenetics. This review provides an overview of these new approaches to managing asthma, including their present status and future potential.
Introduction
The modern age of asthma treatment began more than 50 years ago with the introduction of the fi rst pressurized metered-dose inhaler (pMDI) in 1956 (Crompton 2006) . The pMDI provided convenient delivery of effective bronchodilator therapy. Patients with asthma used the rapidly acting nonselective β-agonists (ie, isoprenaline and epinephrine) through the mid 1960s, when the number of asthma-related deaths skyrocketed (Crompton 2006) . The increased death rate was attributed to a decreased response to nonselective β-agonists that prompted patients to overuse their inhalers. Reduced sensitivity to bronchodilators became recognized as a harbinger of severe, lifethreatening asthma attacks. Subsequent warnings from regulatory agencies markedly reduced the use of the nonselective β-agonists. The selective short-acting β 2 -adrenergic agonist (SABA) salbutamol, called albuterol in the US, replaced the nonselective agents (Crompton 2006) and has been demonstrated to be a safe and effective bronchodilator (Drazen et al 1996; Dennis et al 2000; NAEPP 2007) . During this time, the goal of asthma treatment shifted from managing bronchospasm to preventing infl ammation.
Systemic corticosteroids, long recognized as an effective anti-infl ammatory treatment for asthma, were associated with serious systemic adverse events when used long term (Crompton 2006) . Delivery of inhaled corticosteroids (ICSs) via a pMDI in the early 1970s ushered in a new era of asthma management (Crompton 2006) . By the late 1980s and 1990s, the effi cacy of anti-infl ammatory therapy using ICSs was realized, and ICSs became established as fi rst-line therapy for patients with asthma. However, clinical response to ICS therapy can vary among patients with asthma, and the dose-response curve for ICS treatment plateaus for many effi cacy measures at low to medium doses (NAEPP 2007) ; thus, a need for new therapies became evident. A novel class of asthma therapies was introduced in the 1990s that targeted the synthesis or activity of the leukotriene family of infl ammatory mediators in the pathogenesis of asthma (Holgate et al 1996) . Leukotriene modifi ers (LTMs) generally have been shown to be less effective than ICSs (Ducharme and Di Salvio 2004) , possibly because they target only the leukotriene pathway of infl ammation, whereas ICSs have a broader anti-infl ammatory effect.
Although the selective long-acting β 2 -adrenergic agonist (LABA) salmeterol was introduced as monotherapy in the late 1980s and early 1990s, concerns about the risk of severe asthma attacks associated with SABAs carried over to this class of therapy (Crompton 2006) . Moreover, studies demonstrated that monotherapy with a LABA was insuffi cient to control asthma (Lazarus et al 2001; Lemanske et al 2001) . Concerns regarding the safety of high-dose ICSs (eg, rare cases of adrenal suppression) and fi ndings from randomized, controlled trials showing a more effective reduction in symptoms and exacerbations with a reduced ICS dose and a LABA (eg, salmeterol or formoterol) compared with high-dose ICS alone eventually cemented the role of LABA in the therapeutic armamentarium (Greening et al 1994; Pauwels et al 1997; Crompton 2006) . Indeed, contemporary asthma treatment guidelines recommend add-on LABA to ICS therapy for those patients who do not respond optimally to low-to medium-dose ICS (Crompton 2006; GINA 2007; NAEPP 2007) .
Despite these advances in therapy, which have contributed to declines in asthma morbidity and mortality in the US, asthma continues to pose a signifi cant personal and economic burden (ALA 2006; GINA 2007; NAEPP 2007) . Barriers to improving the burden of asthma are patient variability and poor patient adherence to therapy. In any given patient, the frequency and severity of symptoms, pulmonary function, airway hyper-responsiveness, infl ammation, and exacerbations vary over time (GINA 2007; NAEPP 2007) . Moreover, tremendous inter-patient variability in the natural course and treatment response of asthma is attributed to the interaction of genetic predisposition, individual patient characteristics (eg, obesity, sex, pregnancy) , and exposure to environmental insults (eg, air pollution, allergens, cigarette smoke) (GINA 2007; NAEPP 2007) . Asthma is a complex disorder with multiple phenotypes and genotypes, which contribute to heterogeneity in response to therapy (Szefl er et al 2005; Wechsler and Israel 2005; Hines and McCarver 2006; GINA 2007; NAEPP 2007) . For example, children with an allergic phenotype responded better to ICS therapy than to LTM therapy (Szefl er et al 2005) . Additionally, it has been postulated that differential patient response to therapy with LABAs and SABAs is associated with polymorphisms in the β 2 -adrenergic receptor gene; however, results from small studies are confl icting (Hancox et al 1998; Israel et al 2000; Taylor et al 2000; Dorinsky et al 2004; Israel et al 2004; Bleecker et al 2006; Wechsler et al 2006; Goldman et al 2007) . However, two recent large studies demonstrated that genotype (n = 2630) did not affect treatment response to LABA when administered with ICS (Bleecker et al 2007) . Although lack of response to ICS therapy also has been associated with a specifi c phenotype and genotype (GINA 2007) , poor adherence can be a cause of therapeutic failure. Studies show that overall adherence to ICS therapy is about 50% (Williams et al 2004; Walders et al 2005) . Complex or frequent dosing regimens are associated with poor adherence (Claxton 2001; GINA 2007 ); still, current therapies for asthma often require multiple medications delivered more than once daily (GINA 2007; NAEPP 2007) . Furthermore, asthma may be variable in an individual patient; therefore, fl exible treatment strategies that enable a step up or step down in treatment to achieve asthma control based on changes in symptoms and other facets of the disease are needed (Kips 2002) . In summary, no single treatment approach is appropriate for all patients.
Asthma therapeutics is a rapidly evolving fi eld. Updated expert guidelines on the prevention, diagnosis, and management of asthma are now available. This paper reviews the new guidelines and introduces emerging diagnostic, treatment, and monitoring options for asthma.
Recommendations from current asthma guidelines
Two recently revised expert guidelines review available data and place into perspective the many advances in the pharmacologic treatment of asthma achieved over the past decades. In the US, the National Asthma Education and Prevention Program (NAEPP) of the National Heart, Lung, and Blood Institute publishes and periodically updates diagnosis and management guidelines aimed at translating basic science and clinical research fi ndings into clinical practice and improving patient outcomes. The third edition of the NAEPP guidelines was recently released (NAEPP 2007) . The most current revision to the guidelines from the Global Initiative for Asthma (GINA) reviews recent data and outlines currently accepted strategies for managing asthma from a global perspective (GINA 2007) .
New approaches to managing asthma: a US perspective
In the new updates, the NAEPP and GINA guidelines now recognize that asthma management is governed by three domains: disease severity, control, and response to treatment (GINA 2007; NAEPP 2007) . Categorization of patients as having intermittent, mild persistent, moderate persistent, or severe persistent asthma is useful during initial clinical assessments to establish an initial treatment regimen. However, the severity of symptoms, lung function assessments, exacerbations, and need for SABA typically vary over time. Further, measures of disease severity are relatively insensitive predictors of treatment response. Thus, assessment of asthma control, rather than disease severity, is now considered the preferred approach for routine clinical monitoring and guiding decisions about maintaining or altering treatment (Table 1) (NAEPP 2007) . Asthma control should be assessed at 1-to 6-month intervals by the health care professional (NAEPP 2007). Medication side effects can vary in intensity from none to very troublesome/worrisome. The level of intensity does not correlate to specifi c levels of control, but should be considered in the overall assessment of risk.
Recommended action for treatment (see Figure 1)
• Maintain current step • Regular follow-ups every 1-6 months to maintain control • Consider step-down if well controlled for at least 3 months No cure exists for asthma; however, the use of optimally effective treatment regimens can achieve control (GINA 2007) . Asthma control embodies the dual concepts of minimizing impairment and reducing risk for deterioration and exacerbations (NAEPP 2007) . This new emphasis on regular assessment of asthma control is a key paradigm shift in the updated NAEPP and GINA guidelines. Both sets of guidelines focus on the importance of forming a patient -clinician alliance to foster long-term treatment adherence and achieve optimal asthma control. These guidelines also advocate patient education, the use of guided self-management, and the individualization of treatment plans (GINA 2007; NAEPP 2007) . The educational process begins at diagnosis and continues throughout follow-up care, with the patient (or caregiver in the case of children) and health care provider working together to develop goals and a personalized, written self-management plan. These plans include guidelines for patient-guided adjustment of medications when needed for deteriorating asthma control or exacerbations.
The NAEPP and GINA guidelines discuss the place of available pharmacologic treatments in asthma therapy, categorizing them as drugs used for long-term control or immediate relief of acute symptoms and exacerbations (GINA 2007; NAEPP 2007) . In all age groups and asthma severity levels, SABAs (NAEPP or GINA) and the LABA formoterol (GINA only) are considered the agents of choice for rapid relief of bronchoconstriction or for prevention of exercise-induced asthma. In Europe, formoterol is the only LABA indicated for rapid relief of bronchoconstriction; it is to be used as a reliever only in patients being treated with an ICS. The need for higher or more frequent SABA or LABA doses suggests deteriorating asthma control and is an indication for medical attention and increased therapy.
Stepwise pharmacologic management algorithms for controller therapy are available in both guidelines; the NAEPP has a new 6-step approach, while GINA has revised their 5-step approach. The NAEPP algorithm for adults and adolescents aged 12 years or older is shown in Figure 1 . Figure 1 Asthma management approach based on control for adults and adolescents 12 years of age and older. Abbreviations: EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting β 2 -agonist; LTRA, leukotriene receptor antagonist; PRN, pro re nata (as needed); SABA, short-acting β 2 -adrenergic agonist.
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In both sets of guidelines, low-dose ICSs remain fi rst-line therapy for control of persistent asthma in adults and older children (Figure 1 ) because of their potent anti-infl ammatory effects and effectiveness compared with other therapies (GINA 2007; NAEPP 2007) . Several ICSs are on the market, each with a unique bioavailability and potency profi le. Although studies of equipotent doses are imperfect (Selroos 2007) , the GINA and NAEPP guidelines provide estimated dose ranges for low-dose, medium-dose, and high-dose ICS therapy based on published comparative clinical trials and dose-ranging studies. For example, the NAEPP daily low-dose range is 180-600 µg for budesonide (BUD) DPI and 100-300 µg for fl uticasone (FP) DPI (NAEPP 2007) , whereas the GINA daily low-dose range is 200-400 µg for BUD and 100-250 µg for FP (GINA 2007) . A low dose of an ICS is preferred step 2 therapy; however, monotherapy with a leukotriene receptor antagonist (LTRA) (montelukast, zafi rlukast) or synthesis inhibitor (zileuton; GINA only) also is a recommended alternative treatment for patients aged 5 years or older. Montelukast also is recommended by the NAEPP for patients aged 0-4 years (GINA 2007; NAEPP 2007) . Only the NAEPP guidelines recommend additional alternative choices for step 2 monotherapy -cromolyn (all ages), nedocromil (Ն5 years), and theophylline (Ն5 years). Monotherapy with a LABA is not recommended in either set of guidelines.
Guideline recommendations for patients who do not respond to low-dose ICS therapy (step 2) differ slightly between GINA and NAEPP ( Figure 1 ) (GINA 2007; NAEPP 2007) . In GINA, combination therapy with a lowdose ICS, and a LABA is the preferred next-step treatment for patients aged older than 5 years. In NAEPP, either this combination or a medium-dose ICS are preferred therapy for patients 12 years of age or older (step 3). For patients aged 5-11 years, the NAEPP gives equal preference to treatment with medium-dose ICS or low-dose ICS plus a LABA, LTRA, or theophylline (step 3). For patients whose asthma is not controlled on step 3 therapy, both sets of guidelines list medium-or high-dose ICS plus a LABA (steps 4 and 5 NAEPP, respectively; step 4 GINA) as preferred therapy. Notably, the fi xed-dose combination ICS/LABA inhaler BUD/formoterol (FM) DPI is approved for use as maintenance and reliever therapy in Europe (Rabe et al 2006; Kuna et al 2007) , but is approved only for maintenance use in the US. Combination therapy with a medium-dose ICS plus a LTRA, zileuton (NAEPP Ն12 years; GINA Ն5 years), or sustained-release theophylline are additional options for GINA and NAEPP step 4 therapy. The addition of oral corticosteroids to ICS plus LABA combination therapy is the preferred last step of GINA (step 5) and NAEPP (step 6) therapy. Anti-immunoglobulin E (IgE) treatment (omalizumab) also can be added for patients with allergies who do not respond to conventional therapy.
Finally, studies of asthma treatment in young children are limited; therefore, treatment recommendations are different for young children than for adults and older children (GINA 2007; NAEPP 2007) . Evidence supports the use of ICS as the GINA-and NAEPP-preferred daily controller for infants and young children. The GINA and NAEPP recommend medium-dose ICS as the next-step treatment for children younger than 5 years whose asthma is not well controlled on low-dose ICS alone (GINA 2007; NAEPP 2007) .
New tools and parameters for asthma diagnosis and monitoring
Routine, objective assessment of lung function is necessary to monitor asthma control and evaluate response to treatment. Spirometry, particularly a patient's forced expiratory volume in 1 second (FEV 1 ), and peak expiratory fl ow (PEF) monitoring remain the cornerstones of noninvasive asthma assessment tools available to health care professionals (GINA 2007; NAEPP 2007) . The GINA and NAEPP guidelines acknowledge the emerging research on these techniques. For instance, the NAEPP has added a recommendation to use the FEV 1 /forced vital capacity ratio to classify asthma severity in children older than 4 years because of its sensitivity. Nonetheless, existing pulmonary function tests are effort dependent, requiring some degree of coordination on the part of the patient, and may be impractical for use in young children (GINA 2007) .
Impulse oscillometry is a particularly useful measure of lung function in young children because it requires only passive cooperation (Marotta et al 2003) . The patient breathes normally into a mouthpiece for a short period while a pulseshaped pressure fl ow excitation is delivered to the respiratory system by a loudspeaker. Resistance and reactance of the pulse by the child's respiratory system provides a measure of lung function. Impulse oscillometry has been shown to detect lung function abnormalities in young children at increased risk of persistent asthma, particularly those with atopic disease. In addition to new diagnostic and monitoring methods for lung function, development of new, accurate, and noninvasive tests to assess asthma control and exacerbation risk is proceeding at a rapid pace.
Measurement of biomarkers of lung infl ammation is used in clinical research, and several techniques hold promise for future use in routine clinical practice. Nitric oxide (NO) is one mediator of infl ammation. Clinically, the fractional concentration of exhaled NO (FeNO) distinguishes a patient with asthma not receiving anti-infl ammatory treatment, correlates with other markers of disease severity and infl ammation, and, in some studies, predicts responsiveness to corticosteroid therapy (ATS 2006; NAEPP 2007 ). An analyzer of FeNO is commercially available and has been approved for use in the US (NIOX ® Flex, Aerocrine Inc., New York, USA) (Silkoff et al 2004; Alving et al 2006) , but cost and reimbursement challenges have hindered widespread clinical use (ATS 2006) . Another FeNO monitor that utilizes a biosensor platform and patented Sol-Gel technology is under development (Apieron Inc., Menlo Park, CA, USA). Eosinophils are important effector cells, and elevated levels in the sputum and peripheral blood are another well-recognized marker of infl ammation in asthma. Measurement of sputum eosinophilia represents a possible tool for adjusting asthma therapy to reduce exacerbations in adult patients (Petsky et al 2007) . However, standardization of methodology and the complexity of the measurement process currently limit the usefulness of this technique (NAEPP 2007) . Finally, increased levels of IgE are present in patients with allergic airway infl ammation. Children with elevated serum IgE levels have responded positively to ICS treatment, suggesting that this biomarker may be useful for guiding treatment decisions (Szefl er et al 2005) .
In summary, while the GINA and NAEPP guidelines recognize the potential usefulness of measuring FeNO, sputum eosinophils, and serum IgE, both fall short of recommending the widespread use of these and other biomarkers until further prospective, randomized, controlled studies in adults and children are conducted (GINA 2007; NAEPP 2007) .
Treatment update Monotherapy with an ICS
ICSs are the fi rst line of therapy for control of persistent asthma in adults and older children and considered the most effective anti-infl ammatory treatment (GINA 2007; NAEPP 2007 (Wenzel 1998; Lazarus et al 1998) . Therefore, pretreatment baseline and periodic monitoring of hepatic enzymes is recommended, particularly during treatment initiation (Wenzel 1998) .
Sin et al conducted a systematic review and meta-analysis of therapies used in persistent asthma and concluded that the LTMs (including LTRAs and zileuton) were more effective than placebo in preventing asthma exacerbations, but less effective than ICS (Sin et al 2004) . Indeed, the GINA guidelines consider zileuton to be an alternative, but not preferred, monotherapy for step 2 treatment; the NAEPP and GINA guidelines consider zileuton an alternative add-on therapy for step-up (3 or 4) care for adults and adolescents (Figure 1 ) (GINA 2007; NAEPP 2007) . In patients with aspirin-intolerant asthma, addition of zileuton to usual ICS or oral corticosteroid therapy was associated with improvements in pulmonary function, and symptoms of rhinosinusitis and asthma (Dahlén et al 1998) . A similarly designed study using montelukast was associated with similar benefi ts in patients with aspirinintolerant asthma (Dahlén et al 2002) . Taken together, these studies show the important role of the leukotriene pathway in this disorder. In summary, zileuton may be an appropriate alternative treatment option as monotherapy for patients with mild persistent asthma, particularly those with a distinct asthma phenotype, and as an add-on therapy for patients with moderate or severe persistent asthma.
ICS/LABA combination therapy
The ICSs are considered the most effective anti-infl ammatory treatment for control of persistent asthma, and inhaled β 2 -adrenergic agonists are the most effective bronchodilators New approaches to managing asthma: a US perspective (Barnes 2002; NAEPP 2007) . The ICSs inhibit eosinophils, macrophages, T-lymphocytes, mast cells, and other markers of infl ammation. LABAs may possess anti-infl ammatory properties or other benefi cial pharmacologic effects that complement ICSs, such as inhibiting the release of infl ammatory mediators from mast cells, blocking plasma exudates and reducing airway edema, and modulating airway sensory nerves that mediate airway hyper-responsiveness (Figure 2) .
A Cochrane database systematic review of 30 randomized, controlled studies demonstrated that the addition of a LABA to ICS therapy was more effective than higher dose ICS monotherapy in preventing treatment discontinuations because of deteriorating asthma control in patients with primarily moderate disease (Greenstone et al 2005) . An additional Cochrane review of 10 trials in adults with asthma maintained on moderate to high ICS doses demonstrated that LABA addition enabled an ICS dose reduction with improved or maintained asthma control (Gibson et al 2005) . Combined therapy with low-dose ICS and LABA currently is used extensively for treatment of persistent asthma in the US and Europe.
Recognition of the efficacy and widespread use of combination therapy led to the development of fi xed-dose combination inhalers (Barnes 2002; Miller-Larsson and Selroos 2006 (Pearlman et al 2004; Nathan et al 2006) . The FP/SAL HFA pMDI at the initial formulation dosage of 50/25 µg × 2 inhalations twice daily demonstrated similar effi cacy and tolerability as FP/SAL DPI 100/50 µg × 1 inhalation once daily (Bateman et al 2001) .
In 2000 FM DPI alone (Noonan et al 2006) . Additionally, BUD/FM pMDI demonstrated significantly increased pulmonary function versus its monocomponents in patients with mild to moderate persistent asthma previously treated with ICSs (Corren et al 2007) .
The proprietary formulations of BUD/FM and FP/SAL are available as fi xed doses of the LABA component, with different dose levels of the ICS component, which is useful for patients needing to adjust the dose of corticosteroid. A randomized, controlled study demonstrated that patients stabilized on a high dose of BUD alone could step down to low-dose therapy without loss of symptom or lung function control (Foresi et al 2000) . Furthermore, this study showed that use of a high dose of BUD at the onset of an exacerbation was associated with additional clinical benefi t. Another randomized study showed that as-needed use of FM increased the time to the fi rst severe asthma exacerbation compared with standard rescue therapy (Tattersfi eld et al 2001).
These fi ndings prompted studies to assess whether the BUD/FM combination inhaler was benefi cial when used both as regular maintenance therapy and as-needed reliever therapy for patients needing additional asthma control . The contributions of BUD and FM administered as needed were demonstrated in a study in which patients received BUD/FM (160/4.5 µg × 1 inhalation twice daily) as maintenance therapy plus either terbutaline (0.4 mg), FM (4.5 µg), or BUD/FM (160/4.5 µg) for as-needed rescue medication (Rabe et al 2006) . Patients who used as-needed BUD/FM had a signifi cantly longer time to the fi rst severe exacerbation and a signifi cantly lower rate of severe exacerbations versus patients who used as-needed FM or terbutaline. As-needed FM also signifi cantly increased the time to the fi rst severe exacerbation and reduced the rate of severe exacerbations versus as-needed terbutaline.
In a study evaluating BUD/FM as maintenance and reliever therapy, maintenance treatment with fi xed-dose BUD/FM DPI 80/4.5 µg (administered as 1 inhalation twice daily) or BUD 320 µg (administered as 1 inhalation twice daily), both with as-needed SABA, was compared with maintenance BUD/FM 80/4.5 µg twice daily plus additional inhalations as needed (O'Byrne et al 2005) . The BUD/FM maintenance plus reliever regimen resulted in signifi cantly improved symptom control, pulmonary function, and reduced rates of severe exacerbations and related complications (Figure 3) than either of the fixed-dose plus as-needed SABA regimens (O'Byrne et al 2005) . Another study further demonstrated that maintenance and reliever treatment with BUD/FM (160/4.5 µg × 2 inhalations twice daily then titrated, plus additional inhalations as needed) provided similar improvements in pulmonary function with a reduced risk of exacerbations when compared with titrated fi xeddose FP/SAL (250/50 µg twice daily then titrated) plus asneeded SABA (Vogelmeier et al 2005) . Kuna et al (2007) demonstrated that treatment with BUD/FM, when used as both maintenance (160/4.5 µg × 1 inhalation twice daily) and reliever therapy, signifi cantly increased the time to the fi rst severe exacerbation, reduced the rate of severe exacerbations, and reduced the overall ICS dose compared with treatment with higher doses of fi xed-dose FP/SAL (125/25 µg × 2 inhalations twice daily) or fi xed-dose BUD/FM (320/9 µg × 1 inhalation twice daily) plus as-needed SABA. Improvements in pulmonary function and asthma symptom-control measures were similar among treatments.
In addition, a recent study compared the effi cacy of BUD/FM as maintenance and reliever therapy (160/4.5 µg × 2 inhalations twice daily plus as-needed inhalations) with sustained high-dose FP/SAL (500/50 µg twice daily plus SABA) for 6 months in patients with uncontrolled asthma (Bousquet et al 2007) . BUD/FM as maintenance and reliever therapy signifi cantly reduced the number of total exacerbations and exacerbations requiring hospitalizations/emergency department treatment with signifi cantly less ICS exposure compared with sustained high-dose FP/SAL plus SABA. No differences in the time to the fi rst severe exacerbation, pulmonary function, or asthma symptoms between treatments, however, were observed (Bousquet et al 2007) .
In the US, the Food and Drug Administration (FDA) has required "black box" warnings in the prescribing information for all LABA products, including FP/SAL and BUD/FM combination therapy. It is recommended that LABAs only be used in patients with asthma not adequately controlled on other asthma controller medication (eg, low-to medium-dose ICSs). This safety warning is based on a large (N = 26,355), placebo-controlled trial, which demonstrated that treatment with SAL pMDI 42 µg twice daily (Serevent ® ; Glaxo Wellcome, Middlesex, UK) resulted in an increase in asthmarelated deaths compared with placebo (13/13,176 patients and 3/13,179 patients, respectively) . A retrospective evaluation of these data suggested that the increased risk of asthma-related death was primarily in those who reported using a LABA but not an ICS, at baseline (Nelson 2006) . Moreover, a recent review of 69 trials of patients treated with FM (n = 50,549; 94% prescribed ICS) showed that FM was not associated with increased asthmarelated deaths or serious adverse events (Sears et al 2007) . These studies, as well as earlier LABA data showing a lack of anti-infl ammatory properties and a lack of effi cacy as monotherapy (Nelson 2006) , support that LABAs should be administered in combination with an ICS as recommended in the NAEPP and GINA guidelines (GINA 2007; NAEPP 2007) .
In summary, fi xed-dose combinations of ICS/LABA have recently become the standard of care for patients who are symptomatic on ICS monotherapy. Emerging research suggests additional clinical benefi t for BUD/FM maintenance and reliever therapy. Use of BUD/FM as both rescue and maintenance therapy has gained acceptance outside of the US (GINA 2007) , where the BUD/FM DPI has been available for more than 6 years.
Anti-IgE therapy
Omalizumab (Xolair ® ; Genentech Inc, San Francisco, CA, USA) is a relatively new addition to the asthma treatment armamentarium. This agent is a humanized monoclonal antibody that binds to the Fc portion of circulating IgE antibody on mast cells and basophils, desensitizing mast cells to allergens. The mast cell-stabilizing effect of omalizumab blocks the release of infl ammatory mediators in the lung and reduces IgE levels in response to allergen exposure (Chang and Shiung 2006; Corry and Kheradmand 2006; Strunk and Bloomberg 2006) .
The guidelines recommend consideration of adjunctive omalizumab treatment at steps 5 or 6 of care for patients at least 12 years of age who have allergies and severe persistent asthma not controlled on high-dose ICS/LABA therapy (GINA 2007; NAEPP 2007) . Findings from placebo-controlled trials in adults, adolescents, or children with moderate to severe persistent asthma demonstrate that the addition of subcutaneously administered omalizumab to an existing regimen of high-dose ICS reduced the rate of exacerbations and enabled ICS dose reductions (Busse et al 2001; Milgrom et al 2001; Solèr et al 2001; Humbert et al 2005) . In another placebo-controlled study of patients with severe asthma, omalizumab was not associated with a statistically signifi cant reduction in the exacerbation rate (mean number of asthma exacerbations per patient in the corticosteroid-reduction phase: placebo 0.34, omalizumab 0.19), but the ICS doses needed to achieve control were signifi cantly reduced (Holgate et al 2004) .
In summary, treatment with omalizumab generally is reserved for patients unresponsive to standard ICS therapy who have documented allergic asthma and a serum IgE level between 30 IU and 700 IU (Marcus 2006) . Omalizumab is a considerably more costly treatment than other available asthma treatments, ranging in price from US$6,000 to US$37,000 per year (Marcus 2006) . More widespread use of omalizumab will likely not occur until cost-effectiveness studies demonstrate meaningful cost avoidance (Miller and Reeves 2005; Marcus 2006 ).
Future treatments
Adherence to long-term therapy is an important consideration in the treatment of any chronic disease, and asthma is no exception. A meta-analysis of 76 heterogeneous studies that included electronic monitoring data on medication adherence demonstrated an inverse linear relationship between dosing frequency and rates of adherence (Claxton et al 2001) . The need to simplify therapy and improve medication adherence has fostered the search for novel means of administering existing therapies. Research on new molecular entities with improved pharmacokinetic profi les compared with current medications within existing therapeutic classes is one focus of recent drug development. Another important focus of ongoing drug development efforts revolves around fi nding therapies that target specifi c events in the infl ammatory pathway.
ICS monotherapy
Ciclesonide (Alvesco ® ; ALTANA Pharma AG, Bad Homburg v.d.H. Germany), a novel corticosteroid prodrug that can be administered on a once-daily dosing schedule, has no intrinsic anti-infl ammatory properties. After inhalation, ciclesonide is hydrolyzed in the lung to the pharmacologically active metabolite desisobutyrylciclesonide (Nave 2006) . Commercially available in Europe since 2005, ciclesonide is currently under evaluation by the US FDA. Findings from 2 randomized, double-blind, 12-week, placebo-controlled trials in patients with mild to moderate persistent asthma demonstrated that ciclesonide doses of 80, 160, and 320 µg once daily signifi cantly improved pulmonary function and asthma symptoms and reduced albuterol use compared with placebo (Pearlman et al 2005) . A systematic review of limited comparative phase 2 studies concluded that ciclesonide was as effective as BUD or FP, but the available studies were not suffi cient to determine whether ciclesonide was less likely to suppress hypothalamic-pituitary-adrenal axis function (Dyer et al 2006) . In recent noninferiority studies of patients with mild to moderate asthma, ciclesonide 320 µg once daily was similar to twice-daily BUD 200 µg or FP 200 µg in improving pulmonary function, controlling asthma symptoms, and reducing the need for rescue bronchodilators (Hansel et al 2006; Boulet et al 2007) . The only apparent differences among the ICSs in their adverse event profi les was a signifi cantly higher frequency of oral candidiasis with FP versus ciclesonide (9 vs 0 cases) and a signifi cant decrease from baseline in urinary cortisol concentrations for BUD (400 µg/day) versus ciclesonide (Hansel et al 2006) . Further long-term studies are still needed to determine if any clinically relevant long-term effi cacy or safety advantages exist. A novel submicron particle suspension of BUD for nebulization (Unit Dose Budesonide [UDB]; MAP Pharmaceuticals Inc., Mountain View, CA) recently has been developed for the treatment of asthma. A randomized, double-blind, active-controlled, single-dose, crossover study in healthy volunteers (n = 16) evaluated the pharmacokinetics and safety of UDB administered at three different strengths (0.06 mg, 0.12 mg, and 0.24 mg/2 mL) versus budesonide inhalation suspension (BIS) 0.25 mg/2 mL (Pulmicort Respules ® ; AstraZeneca, Wilmington, DE, USA). UDB was well tolerated in healthy adults. UDB 0.24 mg had a signifi cantly greater C max compared with BIS 0.25 mg. In addition, T max was signifi cantly greater for all three doses of UDB compared with BIS. Thus, UDB is absorbed more rapidly than BIS (Bosco et al 2007) . The clinical signifi cance of this fi nding is unknown; larger clinical trials in adults and pediatric patients with asthma have not been reported.
Combination ICS/LABA therapy
The focus of future development for ICS/LABA therapy is on once-daily dosing with a 24-hour LABA and a LABA with a rapid onset. In the US, the currently available fi xed-dose ICS/LABA inhalers are approved for administration twice daily. Although the ICSs BUD and mometasone have shown effi cacy when administered once daily, currently available LABAs are usually administered twice daily (NAEPP 2007) . Once-daily administration of BUD/FM DPI was investigated in a double-blind, active-control study in 523 patients whose asthma was not fully controlled on ICS alone (Buhl et al 2003) . This study compared once-daily dosing of BUD/ FM 160/4.5 µg × 2 inhalations with twice-daily dosing of BUD/FM 160/4.5 µg × 1 inhalation or once-daily dosing of BUD 400 µg × 1 inhalation. Each treatment resulted in the same total daily dose of budesonide or formoterol. Compared with BUD alone, the fi xed-dose combination of ICS/LABA resulted in signifi cant improvements in pulmonary function (Figure 4) , asthma symptoms, and days free from asthma symptoms or rescue SABA regardless of dosing schedule. No signifi cant differences in asthma control days were observed between the once-daily and twice-daily BUD/FM dosage groups.
Other ICS/LABA combinations are being evaluated for administration from one single inhaler. 
Immunotherapy
Immunotherapies target specifi c elements of asthma pathophysiology. Several different immunotherapeutic approaches are being investigated for the treatment of asthma. Current research includes agents used to treat either atopic or infl ammatory disease states (eg, rheumatoid arthritis).
The role of allergen-specifi c immunotherapy in the treatment of asthma has been extensively studied. A systematic review of 75 trials demonstrated that allergen-specifi c intradermal or subcutaneous immunotherapy (SCIT) for asthma reduced asthma symptoms and medication use and improved bronchial hyper-reactivity (Abramson et al 2003) . Moreover, a recent long-term trial demonstrated that a 3-year course of SCIT given to children and adolescents with grass and/or birch pollen allergy resulted in clinical benefi t and possible prevention of the development of asthma 7 years after therapy (Jacobsen et al 2007) . The new NAEPP guidelines recommend consideration of SCIT at steps 2 to 4 for patients aged 5 years and older who have allergic asthma (NAEPP 2007) . However, the GINA guidelines state that specifi c immunotherapy only be considered if strict environmental avoidance and pharmacologic intervention have been unsuccessful at controlling the patient's asthma (GINA 2007) . Sublingual immunotherapy (SLIT) is being considered as a possible alternative to the subcutaneous route of administration (Passalacqua et al 2004) . Although it is gaining acceptance for treatment of atopic disorders, such as allergic rhinitis, SLIT of allergen extracts represents a new and novel treatment for children with allergic asthma (Sopo et al 2004) . In a systematic review of SLIT using house dust mite, olive pollen, wall pellitory (Parietaria) pollen, and grass pollen, Sopo et al (2004) concluded that only SLIT with house dust mite resulted in low to modest clinical benefi t in children with mild to moderate persistent asthma sensitized to this allergen. However, a different systematic review of 25 studies concluded that SLIT had a modest benefi cial effect on asthma in terms of severity reduction (Calamita et al 2006) . Another study showed that children with hay fever to grass pollen who were treated with SLIT for 3 years had improved allergic rhinitis symptoms and reduced development of seasonal asthma compared with children treated with standard symptomatic therapy (Novembre et al 2004) . These preliminary results with SLIT for asthma treatment and prevention are promising; however, additional studies are needed on effective dose, treatment schedules, and duration of treatment with a specifi c allergy extract in different patient populations .
Rush immunotherapy (RIT) is a procedure that enables rapid desensitization of allergic patients through repeated injections of allergenic extract over a short time period (Cox 2006) . Using this technique, the therapeutic maintenance dose can be achieved in as little as 1-3 days compared with 3-6 months using conventional immunotherapy (Cox 2006) . RIT has demonstrated effi cacy for several inhalant allergens, including dust mite (Kohno et al 1998) , pollen (Movérare et al 2001) , and mold (Horst et al 1990) , although the high incidence of systemic reactions reported with RIT has limited its widespread use (Nelson 2007) . In a study evaluating the effect of omalizumab treatment before initiating RIT on systemic reactions in patients with ragweed allergic rhinitis, fewer and less severe adverse events, including anaphylactic reactions, were observed with omalizumab pretreatment compared with RIT alone (Casale et al 2006) . Further studies are needed to determine the optimal timing and dosing of omalizumab pretreatment in RIT protocols in different patient populations, including those with allergic asthma; however, the results from these studies suggest that RIT may hold promise in the future as a convenient immunotherapy option in allergic patients.
Biologic modifi ers
Tumor necrosis factor-alpha (TNF-α) is an infl ammatory cytokine produced by mast cells and found in the airways of patients with asthma (Rouhani et al 2005) . Several small pilot studies suggest a possible role for blocking the effects of TNF-α in patients with severe, refractory asthma. The TNF-α antagonist, etanercept (Enbrel ® ; Immunex Corporation, Thousand Oaks, CA, USA), administered 25 mg subcutaneously twice weekly for 2 weeks, was evaluated in a randomized, placebo-controlled trial of patients with mild to moderate allergic asthma (n = 26) (Rouhani et al 2005) . No appreciable clinical effect on measures of airway hyperresponsiveness was demonstrated, and the trial was stopped early because one patient developed transient left-sided hemiplegia. In contrast, a placebo-controlled crossover study of patients with refractory asthma (n = 10) demonstrated that a twice-weekly course of etanercept 25 mg for 10 weeks was signifi cantly more effective than placebo in improvement in pulmonary function, asthma symptoms, and quality of life (Berry et al 2006) . The humanized monoclonal antibody against TNF-α, infl iximab (Remicade ® ; Centocor, Malvern, PA, USA), was evaluated in a placebo-controlled trial of patients with moderately severe asthma (n = 38) (Erin et al 2006) . Infl iximab was administered as a 5-mg/kg intravenous infusion at weeks 0, 2, and 6. No signifi cant differences were observed between infl iximab and placebo in the change from baseline for morning PEF (primary endpoint). However, infl iximab treatment resulted in signifi cantly greater improvements in the diurnal variation in PEF and reduced rates of exacerbations compared with placebo. These preliminary fi ndings suggest that larger trials are needed to confi rm the effi cacy of therapies directed against TNF-α.
Tacrolimus is a calcineurin inhibitor used orally as an immunosuppressive agent in organ transplantation (Prograf ® ; Astellas Pharma US, Inc., Deerfi eld, IL, USA) and topically (Protopic ® ; Astellas) in dermatologic conditions, such as psoriasis. The putative mechanism of action of tacrolimus in asthma is inhibition of type 2 T helper (Th2) cytokines and subsequent improvement in airway infl ammation (Matsuo et al 2001; Saeki et al 2004) . A phase 2 trial of aerosolized tacrolimus in patients with asthma recently has been completed (ClinicalTrials.gov 2007d), but the results are not yet published.
Anti-interleukin-5 (IL-5) is another biologic modifi er under investigation in clinical trials. Mepolizumab is one monoclonal antibody against IL-5 that reduces eosinophils in the airways and periphery (Büttner et al 2003; MenziesGow et al 2003) , but a small, phase 1 trial (n = 24) failed to show a salient effect on airway hyper-responsiveness or allergen-induced bronchoconstriction in patients with mild allergic asthma (Leckie et al 2000) . In a small, dose-ranging study (n = 26), another monoclonal anti-IL-5 antibody (SCH55700) produced modest improvements in lung function in patients with severe asthma receiving high-dose ICS or oral corticosteroid therapy, but no change in other clinical endpoints versus placebo (Kips et al 2003) . Determination of a possible role of antibodies directed against IL-5 awaits the results of further clinical trials.
Pharmacogenetics
In the future, pharmacogenetics may offer the opportunity to individualize asthma treatment based on associations between a particular genetic polymorphism and a predicted response to treatment (Wechsler 2006) . Some pharmacogenetic studies have suggested that a homozygous arginine (Arg) genotype at amino acid position 16 of the β 2 -adrenergic receptor is associated with worsening asthma clinical outcomes in patients receiving the SABA albuterol (Taylor et al 2000; Israel et al 2000; Israel et al 2004) or the LABA salmeterol (Weschsler et al 2006) . However, studies with LABAs show conflicting results (Dorinsky et al 2004; Bleecker et al 2006; Hancox et al 1998; Bleecker et al 2007; Goldman et al 2007) . For example, two studies with the largest homozygous Arg population to date (Arg/Arg, n = 430) demonstrated that genotype had no effect on the percentage of patients experiencing severe exacerbations or other clinical outcomes in response to the LABA FM when administered with the ICS BUD (Bleecker et al 2007) . Based on these data, a homozygous Arg/Arg at amino acid position 16 of the β 2 -adrenergic receptor does not appear to affect treatment response to LABAs.
Other pharmacogenetic variations have been identifi ed. For example, studies have suggested that the transcription factor T-bet gene (TBX21) may be involved in the effect of ICS therapy on airway responsiveness in asthma (Tantisira et al 2004; Raby et al 2006) . Heterogenetic response to treatment with LTMs has been reported, which may be attributable to polymorphisms in genes that encode proteins in the LT pathway (Lima et al 2006; Lima 2007) . For example, one study showed that response to treatment with montelukast may be infl uenced by particular polymorphisms in the cysteinyl leukotriene receptor 2, CYSLTR2, and arachidonate 5-lipoxygenase, ALOX5, genes (Klotsman et al 2007) .
Additionally, some pharmacogenetic studies on asthma have demonstrated that polymorphisms in the prostanoid receptor genes PTGER2, PTGER3, PTGER4, PTGIR, and TBXA2R infl uence the pathogenesis of aspirin-intolerant asthma (Kim et al 2007) .
Asthma is a variable disease with individual variation in symptoms and treatment responses. Although none of the genotypes in isolation explain the degree of patient variability in drug response (NAEPP 2007) , future pharmacogenetic studies may identify additional genetic polymorphisms that affect individual treatment response and further elucidate the mechanisms involved in the genetic response to treatment. Pharmacogenetics may be used in the future to predict a patient's response to treatment based on a patient's genotype and allow for individualized treatment (Wechsler 2006; NAEPP 2007) .
Gene therapy
Gene-based vaccines may have a role in immunomodulation for patients who have corticosteroid-resistant asthma or severe asthma requiring systemic corticosteroid therapy (Kolb et al 2006) . It has been postulated that gene therapies targeting the Th2 cell pathway involved in chronic airway infl ammation may be benefi cial in the treatment of asthma (Kolb et al 2006; Wang et al 2007) . Results from Hogan et al (1998) demonstrated suppression of the Th2 response to aerosolized ovalbumin in mice after gene transfer of IL-12, thus inhibiting allergic airways disease. Moreover, overexpression of IL-12 restored local antiviral immunity, which may be relevant in patients who have viral-induced exacerbations (Hogan et al 1998) . Another study in mice showed that allergen-induced airway hyperresponsiveness was signifi cantly inhibited by gene transfer of IFN-γ (Dow et al 1999) . In addition, a study by Mathieu et al (1999) suggested a potential role for gene therapy in corticosteroid-resistant asthma. In vitro gene transfer of the glucocorticocoid receptor gene repressed nuclear factor-κB activities even without exogenous corticosteroids; thus, delivery of this gene may restore corticosteroid sensitivity in corticosteroid-resistant patients (Mathieu et al 1999) .
Conclusion
Current treatment strategies approach asthma as a relatively homogeneous disease, addressing inflammation, bronchoconstriction, and airway hyper-responsiveness using corticosteroids, SABAS, LABAS, LTMs, and other pharmacologic agents. Although signifi cant inroads to better patient outcomes have been achieved using currently available treatments, barriers to effective asthma control continue to exist, in part because of variability in treatment response and issues with treatment adherence.
The most recent asthma management guidelines, put forth by the NAEPP and GINA in 2007, provide updated recommendations in an effort to optimize asthma treatment and standardize approaches to diagnosis and assessment, all while retaining a focus on the individual. Recommendations include an initial evaluation of asthma severity followed by continued monitoring of asthma control at follow-up visits, factoring in the element of treatment responsiveness. In addition, the guidelines outline a step-wise approach to managing asthma, providing treatment recommendations for each step based on the most recent effi cacy and tolerability data. These recommendations are meant to assist clinicians in making treatment decisions; however, health care providers also must consider a variety of additional factors, including the patient's asthma history and the likelihood of a patient to adhere to a particular treatment.
The goal of many newly available or emerging treatment approaches has been to provide effective, safe, and simple treatment options for patients with asthma. Other emerging treatments combine existing agents that have unique and complementary anti-inflammatory and bronchodilatory actions, such as the combination of FP/SAL administered via HFA pMDI and BUD/FM administered via DPI. BUD/FM has demonstrated a fast onset of action and effectiveness as maintenance and reliever therapy. This approach allows therapy to be tailored to an individual's changing needs. BUD/ FM as maintenance and reliever therapy is currently only available outside of the US. Other ICS/LABA combination therapies that are in development and offer promise include the combinations of ciclesonide/FM, mometasone/FM, and mometasone/indacaterol, all of which have rapidly acting LABAs. The monoclonal antibody therapy omalizumab, which is recommended in combination with high-dose ICS plus LABA by the recent NAEPP and GINA guidelines, offers a unique approach to treating patients with severe allergic asthma that is not controlled with high-dose ICS plus LABA. The novel immunotherapy anti-TNF-α antibody etanercept also is being investigated for the treatment of patients with severe asthma.
The variety of existing and emerging treatment options that address multiple facets of asthma offer promise for reducing the substantial health care and economic burden of asthma. In the near future, the development of more specialized diagnostic tests and the use of more individualized approaches to asthma management will be critical for further improving asthma outcomes. Research is currently underway to better understand the causes of inter-and intra-patient variability in treatment response, focusing on factors, such as obesity, genetic predisposition, and gene-environment interactions. Identifi cation of risk factors that contribute to differential response to treatment will aid clinicians in selecting the optimal treatments for their patients.
